What is Parallel Fluidics?
Parallel Fluidics operates as a specialized manufacturer providing the world's first on-demand microfluidic production service. The company addresses the inherent risks associated with traditional device development by offering production-grade components from the initial design phase. This approach significantly reduces time-to-market for innovators in sectors such as drug discovery, sequencing, and cell therapy. By streamlining the transition from laboratory concept to scalable product, Parallel Fluidics empowers scientific organizations to accelerate their research cycles and improve patient outcomes through reliable, high-performance microfluidic solutions.
How much funding has Parallel Fluidics raised?
Parallel Fluidics has raised a total of $8.8M across 2 funding rounds:
Unspecified
$1.8M
Angel/Seed
$7M
Unspecified (2021): $1.8M, investors not publicly disclosed
Angel/Seed (2024): $7M led by Praxis, 8VC, and J2 Ventures
Key Investors in Parallel Fluidics
8VC
8VC is a prominent technology investment firm that focuses on backing industry-transforming companies, with a strong emphasis on Bio-IT and smart enterprise platforms.
J2 Ventures
J2 Ventures is an investment firm specializing in early-stage companies that pioneer technologies in biomedical engineering and advanced computing, often led by a team of scientists and physicians.
Praxis
Praxis is a venture capital firm that provides strategic backing to innovative startups, focusing on long-term growth and technological advancement.
What's next for Parallel Fluidics?
With this major enterprise-level funding, Parallel Fluidics is poised to expand its manufacturing footprint and enhance its proprietary production technology. The strategic roadmap likely involves scaling operations to meet the increasing demand for precision medicine and diagnostic tools, while simultaneously deepening its integration into the drug discovery pipeline. By leveraging the expertise of its high-profile backers, the company is expected to focus on operational efficiency and market penetration, ensuring that its on-demand manufacturing model becomes the industry standard for microfluidic development. Future growth will likely center on diversifying its service offerings to support more complex biological applications and expanding its reach within the global life sciences ecosystem.
See full Parallel Fluidics company page
